No Data
Caribou Biosciences, Inc. (NASDAQ:CRBU) Is a Favorite Amongst Institutional Investors Who Own 62%
Insider Purchase: Chief Financial Officer of $CRBU Buys 17,360 Shares
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $11
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Express News | Reported Earlier, Caribou Biosciences Advances CB-010, CB-011, And CB-012 Programs With Key Clinical Updates Expected In 2025; Cash Position $281M
Caribou Biosciences Initiates Phase 1 Clinical Trials for CB-010 in Lupus and Advances Multiple CAR-T Therapy Programs
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
HOHA888 : Hi what do you think is a good TP target? My average is around $1.50
FattyChick OP HOHA888 : >1.70
HOHA888 FattyChick OP : okay thanks!
FattyChick OP HOHA888 : Long term >$6
HOHA888 FattyChick OP : Long term as in? Abt half a year?
View more comments...